Liraglutide vs Teriparatide

Weeks to months

Months (titrated over weeks)

Months to years

Especially during dose escalation

Over ~18-24 months of daily use

Over ~18-24 months

Detectable by ~3 months

Hours after each dose

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).

N Engl J Med (2016) · Rct · n=9340

Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide (up to 1.8 mg/day) vs placebo, median follow-up 3.8 years

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).

N Engl J Med (2015) · Rct · n=3731

56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

JAMA (2015) · Rct · n=846

56-week double-blind RCT in 846 adults with overweight/obesity AND type 2 diabetes, liraglutide 3.0 mg vs 1.8 mg vs placebo (2:1:1)

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

N Engl J Med (2001) · Rct · n=1637

Pivotal Fracture Prevention Trial: 1637 postmenopausal women with prior vertebral fractures randomized to PTH(1-34) 20 or 40 microg/day or placebo, median 21 months

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Lancet (2018) · Rct · n=1360

Head-to-head double-blind, double-dummy RCT of teriparatide 20 microg/day vs risedronate 35 mg/week in 1360 women with severe osteoporosis over 24 months

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

N Engl J Med (2007) · Rct · n=428

18-month randomized, double-blind, controlled head-to-head trial in 428 patients with glucocorticoid-induced osteoporosis